Lariam

(mefloquine)

ApprovedSmall molecule

Mefloquine is used to prevent and treat malaria, a serious disease spread by mosquitoes in tropical regions around the world.[2] Lariam is currently approved and in use across 4 indications[4].[1]

Lariam is one of 140 small molecule programs targeting COVID-19. It is currently in Approved.

Indications

Total Trials

Active Trials

139

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

COVID-19Approved

Plasmodium Falciparum MalariaApproved

HIV InfectionApproved

ProphylaxisCompleted

COVID-19Approved

Approved

Plasmodium Falciparum MalariaApproved

Approved

HIV InfectionApproved

Approved

ProphylaxisPreclinical

Completed

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Lariam

UUnited BioPharma

Approved

21 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Nitrostat

VViatris Specialty LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria7 trials

Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00082576·238 enrolled

A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

Completed·OORIYOMI OMOTOYOSI AKINYOTU·Phase 1·NCT02524444·142 enrolled

Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.

Completed· Pfizer logo

Pfizer·Phase 3·NCT00367653·397 enrolled

Show 4 more trials

Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02612545·216 enrolled

The Effect of Malaria on Disease Progression of HIV/AIDS

Completed·LLondon School of Hygiene and Tropical Medicine·N/A·NCT00499876·197 enrolled

Antimalarial Drug Resistance in Mali

Completed·CCenters for Disease Control and Prevention·N/A·NCT00127998·1,011 enrolled

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

Completed·UU.S. Army Medical Research and Development Command·N/A·NCT00761020·31 enrolled

ART2 trials

Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects

Completed·UUniversity of Oxford·Phase 4·NCT02324738·16 enrolled

Assessment of Artesunate/Mefloquine in the Peruvian Amazon

Completed·IInstituto Nacional de Salud. Peru·Phase 4·NCT02084602·45 enrolled

Combination Therapy2 trials

In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy

Completed·GGlobal Emerging Infections Surveillance and Response System·Phase 4·NCT01976780·118 enrolled

Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand

Completed·—·N/A·NCT01659281·13 enrolled

Pregnancy2 trials

Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy

Completed·HHospital Clinic of Barcelona·N/A·NCT00811421·5,820 enrolled

Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine

Completed·IInstitut de Recherche pour le Developpement·Phase 3·NCT00970879·430 enrolled

Prophylaxis1 trial

Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial

Completed·IInstitute of Tropical Medicine, Belgium·N/A·NCT00373048·300 enrolled

7 more indications

Trial1 trial

Kilimanjaro IPTi Drug Options Trial

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 2/3·NCT00158574·2,419 enrolled

Effectiveness1 trial

A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19

Completed·BBurnasyan Federal Medical Biophysical Center·Phase 2/3·NCT04347031·320 enrolled

Glioblastoma Multiforme1 trial

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01430351·144 enrolled

Plasmodium Falciparum1 trial

A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT02488902·521 enrolled

Urinary Schistosomiasis1 trial

Activity of Mefloquine Against Urinary Schistosomiasis

Completed·—·Phase 2·NCT01132248·65 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Terminated· Biogen logo

Biogen·Phase 1/2·NCT00746941·37 enrolled

Unspecified1 trial

An Evaluation of Weekly Tafenoquine

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT02488980·306 enrolled

Regulatory

FDA Approval Timeline[5]

May 2, 1989

LARIAM

NDA NDA019591

May 2, 1989

MEFLOQUINE HYDROCHLORIDE

NDA NDA019578

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for mefloquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Lariam drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — mefloquine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for mefloquine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA019591). U.S. Food & Drug Administration.
[6]
SEC EDGAR — United BioPharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: UUnited BioPharma

Lariam

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Malaria7 trials

ART2 trials

Combination Therapy2 trials

Pregnancy2 trials

Prophylaxis1 trial

Trial1 trial

Effectiveness1 trial

Glioblastoma Multiforme1 trial

Plasmodium Falciparum1 trial

Urinary Schistosomiasis1 trial

Progressive Multifocal Leukoencephalopathy1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News